The present study provides novel mechanistic insights into the therapeutic potential of targeting SCAMP3 in breast cancer and reveals that the combination of EGFR inhibitors and SCAMP3 depletion displays promising activity to enhance therapeutic responsiveness in patients with resistance to EGFR TKI. The gene discussed is EGFR; the disease is breast cancer.